Sutro Biopharma (STRO) Current Deferred Revenue (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Current Deferred Revenue data on file, last reported at $10.6 million in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue fell 84.86% year-over-year to $10.6 million; the trailing twelve-month figure through Dec 2025 stood at $10.6 million (down 84.86% YoY), and the FY2025 full-year result was $10.6 million, down 84.86% from the prior year.
• Current Deferred Revenue rose to $10.6 million in Q4 2025, from $9.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $74.0 million in Q2 2024 to a low of $5.5 million in Q4 2021.
• A 5-year average of $24.8 million and a median of $16.3 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 310.09% in 2024 and slumped 87.63% in 2025, its largest moves.
• Tracing STRO's Current Deferred Revenue over 5 years: stood at $5.5 million in 2021, then surged by 204.93% to $16.8 million in 2022, then advanced by 23.31% to $20.7 million in 2023, then surged by 237.67% to $69.8 million in 2024, then plunged by 84.86% to $10.6 million in 2025.
• Business Quant data shows STRO's Current Deferred Revenue at $10.6 million in Q4 2025, $9.0 million in Q3 2025, and $12.0 million in Q2 2025.